Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trialPierre‐François Laterre, Bruno François, Fernando Martínez‐Sagasti et al.|Journal of Critical Care|2023Cited by 11